Find here all our blog posts tagged with: MDR-IVDR.

Three distinct colored light paths converging on an abstract glowing medical device against a dark background.

Three Regulators, Three Different Bets on AI Medtech

The EU, the US, and China are sequencing AI device oversight in opposite orders, and compliance leaders need to plan for all three.

Abstract visualization of a clinical AI decision network with some data connections rendered sharp and others fading into static.

Clinical Decision Support AI: Cleared, Not Proven

High-risk AI clinical decision support is scaling through FDA and IVDR pathways faster than its evidence base, leaving compliance leaders to close the gap regulators haven't.

A surgical tray under split lighting, part crisp and part blurred, evoking a medical AI system in continuous change after approval.

Clearance Was Never the Finish Line

FDA's predetermined change control pathway shifts the real compliance burden from initial authorization to lifecycle governance of AI models after they ship.

A hand balances a scale between a stack of paper files and a shifting glowing sphere, symbolizing documentation valued against an unsettled standard.

The MedTech Compliance Asset Has a Shelf Life

MedTech buyers are pricing compliance documentation as a deal asset, but the standards that file is graded against are still being written.

Three tinted glass panes with faint internal patterns, symbolizing diverging regulatory views of the same technology.

HealthTech Buyers Are Pricing Compliance Before the Rules Agree With Each Other

Diligence teams valuing AI-enabled health devices are treating EU AI Act readiness as a settled asset, but FDA, EU, and China are still diverging on what that documentation must show.

A medical AI device shown updating freely on one side and sealed under multiple regulatory stamps on the other.

The Continuous-Update Trap in Medical AI Governance

FDA now lets manufacturers update AI devices without new submissions, but EU's MDR/IVDR and AI Act stack offers no equivalent, forcing a split lifecycle strategy.

Split image showing a non-specialist technician capturing an ultrasound scan on one side and a remote physician interpreting it on the other, linked by a data connection.

The Decoupled Diagnostic: Who Owns the Scan

FDA's clearance of AI that lets non-specialists capture diagnostic scans creates a workflow no existing device framework was built to assign liability for.

A clock partially submerged in water with its gears exposed, symbolizing a regulatory deadline that has moved but not disappeared.

The EU AI Act Extension Is a Delay, Not a Reprieve

The Digital Omnibus pushes the EU AI Act high-risk deadline for medical devices to August 2027, but MDR/IVDR and EMA already require the same work now.

An hourglass on a steel table in a dim clinical corridor, sand falling, symbolizing a regulatory countdown for medical device AI.

The EU AI Act Grace Period Is a Countdown, Not a Pause

Brussels pushed high-risk AI enforcement for medical devices to 2027 and 2028, but the multi-year MDR/IVDR build-out clock is already running.

A partially disassembled clock with exposed gears standing in a sterile hospital corridor, symbolizing misaligned regulatory timelines.

The EU AI Act Reprieve Is a Timing Bet, Not a Pause

Digital Omnibus alignment gives AI-enabled medical devices breathing room on paper, but MDR/IVDR certification obligations have not moved and neither has the underlying risk.

A regulator's desk piled with paper trial records next to a blueprint of an AI data center visible through the window, illustrating the gap between infrastructure investment and regulatory evidence capacity.

Capital Is Flowing to AI. Regulatory Science Capacity Is Not.

EU device rules, FDA benchmarking, and pharma's AI rollout share one constraint: regulators lack the evidence infrastructure to keep pace with deployment.

A glass boundary dividing a clinical space into two zones of light, symbolizing a shifting regulatory classification line.

The Qualification Test That Redraws the AI Device Line

A new EU Court judgment on medical device qualification means AI tools built as informational or decision-support software may already sit inside MDR and IVDR scope.

Abstract photograph of a robotic inspection arm scanning a circuit board with layered light beams, symbolizing automated quality inspection.

The Inspection Layer's Governance Gap

Deep learning inspection tools are moving into FDA and MDR/IVDR-regulated production lines faster than the validation methods built to certify them.

Two diverging streams of light representing separate regulatory paths converging near an abstract anatomical form.

The FDA-EU Fork in AI-Enabled Medical Devices

FDA is building adaptive, lifecycle-based pathways for AI-enabled devices while the EU stacks AI Act obligations atop MDR and IVDR, forcing a sequencing decision now.

Abstract streams of glowing data particles converging into a single current against a dark clinical backdrop.

Routine Health Data Is Fueling AI Devices Faster Than FDA Can Define the Standard

FDA's December 2025 real-world evidence guidance lets sponsors train AI devices on routine health data, but provenance and bias standards remain undefined.

Three interlocking mechanical clocks running at different speeds, symbolizing misaligned regulatory timelines for AI-enabled medical devices.

Three Regulators, Three Clocks, One AI-Enabled Device

The EU, US, and China are each running statute ahead of certification infrastructure for AI-enabled medical devices, and manufacturers need one documentation architecture, not three.

A robotic surgical arm glowing with fiber-optic light inside a sterile operating theater.

The AI Lifecycle Decision Medtech Can't Wait to Make

J&J's Monarch clearance shows predetermined change control plans already govern AI updates, a lifecycle discipline device makers need now, not after genAI guidance lands.

A bridge cable splitting into two diverging strands over water, symbolizing regulatory paths that have not yet converged.

The PCCP's Global Convergence Is a Hypothesis, Not Yet a Standard

IMDRF has laid out principles for regulators to adopt predetermined change control plans, but FDA and the EU's MDR/IVDR regime remain far from aligned.

Abstract split-path image representing generative AI diverging between regulated clinical devices and unregulated drug discovery applications

Generative AI Isn't Breaking Device Rules. It's Avoiding Them.

FDA's generative AI vacuum in clinical SaMD is pushing vendor activity toward drug discovery applications that sit outside device regulation entirely.

A luminous bridge connecting two distinct rock formations, symbolizing a unified regulatory pathway between separate compliance regimes.

The PCCP Window Before the AI Act Deadline Closes

IMDRF's new PCCP principles and the EU AI Act's delayed medtech deadline create a narrow window to build one change control architecture instead of two.

A luminous DNA strand splits into two diverging paths of blue and amber light across a dark laboratory floor.

Pharma's AI Pipeline Is Running on Two Regulatory Clocks

Drug discovery AI is accelerating faster than either the EU AI Act or FDA's generative AI framework can stabilize, forcing pharma to classify now or re-litigate later.

A single medical device evidence file shown split between a loosely organized real-world data set and a rigorously documented data governance binder.

FDA Loosens the Data Bar. The EU Hasn't Said It Will Follow.

FDA's new real-world evidence flexibility for AI devices creates a sequencing risk for manufacturers still reconciling MDR/IVDR and EU AI Act data governance demands.

A human silhouette made of light particles dissolving between physical form and abstract data streams in a clinical setting.

Simulation-Guided Trials Are Ahead of the Law

Digital twins and virtual control arms are entering pivotal trial design faster than GDPR and MDR frameworks can validate the data behind them.

Two diverging paths of light, one narrow and bounded and one diffuse and branching, symbolizing split regulatory tracks for medical AI

Two Speeds of FDA AI Clearance

The FDA's bounded-diagnostic clearances and its generative-AI comment period reveal a widening split in medical AI oversight that regulated buyers must plan around now.